The ADDITION study (ADDITION-DK trial / ADDITION-PRO)
Intensive, multifactorial treatment of people with screendetected type 2 diabetes (ADDITION-DK trial)
Understanding cardiovascular risk and disease progression among individuals with a high-risk of developing diabetes (ADDITION-PRO).
Læs mere
The Population studies in Greenland
The Inuit Health in Transition study is a general health study among adults in Greenland.
Læs mere
A new Danish Diabetes Register
By linkage of several Danish disease registers, Clinical Epidemiology has established a new National Diabetes Register.
Læs mere
PRESET study
Evaluation of methods for measuring gastrointestinal transit and food reward in healthy individuals.
Læs mere
Andre samarbejder/kohorter
The Steno T1 Risk Engine
A screening method for cardiovascular disease in people with type 1 diabetes.
Læs mere
RHAPSODY - "Risk Assessment and Progression of Diabetes"
The RHAPSODY project aims at identifying, characterizing and validating biomarkers for onset of diabetes / diabetes progression in order to enable disease modification. By combining clinical and genetic data from several European cohorts, changes in glucose metabolism before and after diabetes onset will be assessed in order to establish biomarkers of glucose dysregulation potential involvement of genetic factors.
RHAPSODY involves several academic and industrial partners, where SDCC works particularly with the Lund University Diabetes Centre, (Malmö, Sweden), the Swiss Institute of Bioinformatics (Lausanne, Switzerland) and Novo Nordisk (Måløv, Denmark).
The RHAPSODY website
Whitehall-II
The Whitehall II study is a longitudinal study of a cohort of UK civil servants. Between August, 1985, and April, 1988, a total of 10,308 participants working in the London, UK offices of 20 Whitehall departments and aged 35–55 years were recruited (phase 1), and followed up in ten subsequent phases, with every second phase (i.e. phases 1, 3, 5, 7, 9 and 11) including a clinical health examination. Most recent follow-up examination was performed in 2015-16. The Clinical Epidemiology group has taken part in several collaborations on based on data from the study.
The Whitehall-II study website
Inter-99
Inter99 is a population-based primary prevention study of cardiovascular disease.